Calcimedica announces upcoming presentations and events in september

La jolla, calif. , sept. 6, 2023 /prnewswire/ -- calcimedica inc. ("calcimedica") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that rachel leheny, ph.d.

CALC Ratings Summary

CALC Quant Ranking